Hosted by Dailymotion. For legal issues report at the Copyright Center, report us on DMC, or use the Instant Removal tool.
Novavax Vaccine
Description
On Friday, Novavax ($NVAX@US) announced that they would be delaying their COVID-19 vaccine emergency authorization submission until their fourth quarter. Novavax is still poised to produce over 250 million doses of the vaccine by the end of the fourth quarter. Shares of Novavax are trading 18.85% lower at press time.
More from User
00:55
Apple Hikes Incoming
Benzinga
00:58
Trump Settles Niece Lawsuit
Benzinga
00:58
House Eyes Airline Rules
Benzinga
00:57
Intel-Apple Deal
Benzinga
00:50
Senate Targets Buybacks
Benzinga
00:58
CarMax Stock Sinks
Benzinga
Related Videos
00:23
Novavax Jumps 13% After UK Deal For 60 Million Doses Of COVID Vaccine
Wochit
00:23
Novavax Jumps 13% After UK Deal For 60 Million Doses Of COVID Vaccine
Wochit Business
00:23
Novavax Jumps 13% After UK Deal For 60 Million Doses Of COVID Vaccine
Wochit Tech
01:21
U.S. Gives $1.6B to Novavax to Deliver 100M Doses of Potential COVID-19 Vaccine by 2021
Veuer
00:23
Novavax Jumps 13% After UK Deal For 60 Million Doses Of COVID Vaccine
Wochit Entertainment
00:50
FDA, inaasahang mabibigyan ng EUA ang Novavax COVID-19 vaccine; Novavax COVID-19 vaccine, pinakamabisa umano laban sa Delta variant
PTVPhilippines